223 related articles for article (PubMed ID: 27273569)
21. The role of posttranslational modifications of α-synuclein and LRRK2 in Parkinson's disease: Potential contributions of environmental factors.
Pajarillo E; Rizor A; Lee J; Aschner M; Lee E
Biochim Biophys Acta Mol Basis Dis; 2019 Aug; 1865(8):1992-2000. PubMed ID: 30481588
[TBL] [Abstract][Full Text] [Related]
22. LRRK2 expression in idiopathic and G2019S positive Parkinson's disease subjects: a morphological and quantitative study.
Sharma S; Bandopadhyay R; Lashley T; Renton AE; Kingsbury AE; Kumaran R; Kallis C; Vilariño-Güell C; O'Sullivan SS; Lees AJ; Revesz T; Wood NW; Holton JL
Neuropathol Appl Neurobiol; 2011 Dec; 37(7):777-90. PubMed ID: 21696411
[TBL] [Abstract][Full Text] [Related]
23. Atypical Ubiquitination and Parkinson's Disease.
Buneeva O; Medvedev A
Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35409068
[TBL] [Abstract][Full Text] [Related]
24. Overview of the Impact of Pathogenic LRRK2 Mutations in Parkinson's Disease.
Ito G; Utsunomiya-Tate N
Biomolecules; 2023 May; 13(5):. PubMed ID: 37238714
[TBL] [Abstract][Full Text] [Related]
25. Dopamine D2 receptor-mediated neuroprotection in a G2019S Lrrk2 genetic model of Parkinson's disease.
Tozzi A; Tantucci M; Marchi S; Mazzocchetti P; Morari M; Pinton P; Mancini A; Calabresi P
Cell Death Dis; 2018 Feb; 9(2):204. PubMed ID: 29434188
[TBL] [Abstract][Full Text] [Related]
26. Novel LRRK2 GTP-binding inhibitors reduced degeneration in Parkinson's disease cell and mouse models.
Li T; Yang D; Zhong S; Thomas JM; Xue F; Liu J; Kong L; Voulalas P; Hassan HE; Park JS; MacKerell AD; Smith WW
Hum Mol Genet; 2014 Dec; 23(23):6212-22. PubMed ID: 24993787
[TBL] [Abstract][Full Text] [Related]
27. Fbxl18 targets LRRK2 for proteasomal degradation and attenuates cell toxicity.
Ding X; Barodia SK; Ma L; Goldberg MS
Neurobiol Dis; 2017 Feb; 98():122-136. PubMed ID: 27890708
[TBL] [Abstract][Full Text] [Related]
28. Leucine-rich repeat kinase 2 is associated with the endoplasmic reticulum in dopaminergic neurons and accumulates in the core of Lewy bodies in Parkinson disease.
Vitte J; Traver S; Maués De Paula A; Lesage S; Rovelli G; Corti O; Duyckaerts C; Brice A
J Neuropathol Exp Neurol; 2010 Sep; 69(9):959-72. PubMed ID: 20720502
[TBL] [Abstract][Full Text] [Related]
29. Nrf2 mitigates LRRK2- and α-synuclein-induced neurodegeneration by modulating proteostasis.
Skibinski G; Hwang V; Ando DM; Daub A; Lee AK; Ravisankar A; Modan S; Finucane MM; Shaby BA; Finkbeiner S
Proc Natl Acad Sci U S A; 2017 Jan; 114(5):1165-1170. PubMed ID: 28028237
[TBL] [Abstract][Full Text] [Related]
30. LRRK2 Kinase Activity Does Not Alter Cell-Autonomous Tau Pathology Development in Primary Neurons.
Henderson MX; Changolkar L; Trojanowski JQ; Lee VMY
J Parkinsons Dis; 2021; 11(3):1187-1196. PubMed ID: 33720852
[TBL] [Abstract][Full Text] [Related]
31. Leucine-Rich Repeat Kinase 2 interacts with Parkin, DJ-1 and PINK-1 in a Drosophila melanogaster model of Parkinson's disease.
Venderova K; Kabbach G; Abdel-Messih E; Zhang Y; Parks RJ; Imai Y; Gehrke S; Ngsee J; Lavoie MJ; Slack RS; Rao Y; Zhang Z; Lu B; Haque ME; Park DS
Hum Mol Genet; 2009 Nov; 18(22):4390-404. PubMed ID: 19692353
[TBL] [Abstract][Full Text] [Related]
32. LRRK2 regulates endoplasmic reticulum-mitochondrial tethering through the PERK-mediated ubiquitination pathway.
Toyofuku T; Okamoto Y; Ishikawa T; Sasawatari S; Kumanogoh A
EMBO J; 2020 Jan; 39(2):e100875. PubMed ID: 31821596
[TBL] [Abstract][Full Text] [Related]
33. The E3 ligase TRIM1 ubiquitinates LRRK2 and controls its localization, degradation, and toxicity.
Stormo AED; Shavarebi F; FitzGibbon M; Earley EM; Ahrendt H; Lum LS; Verschueren E; Swaney DL; Skibinski G; Ravisankar A; van Haren J; Davis EJ; Johnson JR; Von Dollen J; Balen C; Porath J; Crosio C; Mirescu C; Iaccarino C; Dauer WT; Nichols RJ; Wittmann T; Cox TC; Finkbeiner S; Krogan NJ; Oakes SA; Hiniker A
J Cell Biol; 2022 Apr; 221(4):. PubMed ID: 35266954
[TBL] [Abstract][Full Text] [Related]
34. The role of ubiquitin linkages on alpha-synuclein induced-toxicity in a Drosophila model of Parkinson's disease.
Lee FK; Wong AK; Lee YW; Wan OW; Chan HY; Chung KK
J Neurochem; 2009 Jul; 110(1):208-19. PubMed ID: 19457126
[TBL] [Abstract][Full Text] [Related]
35. Neurodegenerative phenotypes in an A53T α-synuclein transgenic mouse model are independent of LRRK2.
Daher JP; Pletnikova O; Biskup S; Musso A; Gellhaar S; Galter D; Troncoso JC; Lee MK; Dawson TM; Dawson VL; Moore DJ
Hum Mol Genet; 2012 Jun; 21(11):2420-31. PubMed ID: 22357653
[TBL] [Abstract][Full Text] [Related]
36. Upregulation of the p53-p21 pathway by G2019S LRRK2 contributes to the cellular senescence and accumulation of α-synuclein.
Ho DH; Seol W; Son I
Cell Cycle; 2019 Feb; 18(4):467-475. PubMed ID: 30712480
[TBL] [Abstract][Full Text] [Related]
37. Parkinson's Disease-Associated LRRK2 Hyperactive Kinase Mutant Disrupts Synaptic Vesicle Trafficking in Ventral Midbrain Neurons.
Pan PY; Li X; Wang J; Powell J; Wang Q; Zhang Y; Chen Z; Wicinski B; Hof P; Ryan TA; Yue Z
J Neurosci; 2017 Nov; 37(47):11366-11376. PubMed ID: 29054882
[TBL] [Abstract][Full Text] [Related]
38. Human R1441C LRRK2 regulates the synaptic vesicle proteome and phosphoproteome in a Drosophila model of Parkinson's disease.
Islam MS; Nolte H; Jacob W; Ziegler AB; Pütz S; Grosjean Y; Szczepanowska K; Trifunovic A; Braun T; Heumann H; Heumann R; Hovemann B; Moore DJ; Krüger M
Hum Mol Genet; 2016 Dec; 25(24):5365-5382. PubMed ID: 27794539
[TBL] [Abstract][Full Text] [Related]
39. Adenoviral-mediated expression of G2019S LRRK2 induces striatal pathology in a kinase-dependent manner in a rat model of Parkinson's disease.
Tsika E; Nguyen AP; Dusonchet J; Colin P; Schneider BL; Moore DJ
Neurobiol Dis; 2015 May; 77():49-61. PubMed ID: 25731749
[TBL] [Abstract][Full Text] [Related]
40. LRRK2 inhibition does not impart protection from α-synuclein pathology and neuron death in non-transgenic mice.
Henderson MX; Sengupta M; McGeary I; Zhang B; Olufemi MF; Brown H; Trojanowski JQ; Lee VMY
Acta Neuropathol Commun; 2019 Feb; 7(1):28. PubMed ID: 30808409
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
